Horizon Space Acquisition II and SL Bio announce merger

[05-12-2025] Horizon Space Acquisition II Corp. (Nasdaq: HSPT), a special purpose acquisition company currently valued at $92.25 million, and SL Bio Ltd., a clinical-stage biomedical firm, have agreed to a business combination that will see the newly formed SL Science Holding Limited listed on the Nasdaq Stock Market. The completion of this merger is subject to customary closing conditions, including approvals from regulators and shareholders.

SL Bio, which specializes in cellular and gene therapies for cancer treatment and skin care, aims to transform the healthcare landscape through scientific innovation. The company’s proprietary platforms include next-generation immunotherapies designed to bolster the immune response to cancer while reducing risks associated with traditional treatments. SL Bio’s pipeline focuses on high-need indications, such as blood, pancreatic, and brain cancers.

The merger terms stipulate that Horizon Space Acquisition II Corp. will merge with a subsidiary of the combined company, followed by a second merger involving SL Bio and another subsidiary. Shareholders of both companies will receive ordinary shares in the combined entity as consideration. These shares are expected to be listed and traded on Nasdaq following the transaction’s consummation.